Sentinel Node Total Tumour Load As a Predictive Factor for Non-Sentinel Node Status in Early Breast Cancer Patients – The porttle study

• Author(s): Fougo, JL ; Amendoeira, I ; Brito, MJ ; Correia, AP ; Gonçalves, A ; Honavar, M ; Machado, A ; Magalhães, A ; Marta, S ; Nogueira, M ; Peleteiro, B ; Pontes, P
• Date: 2020
• Persistent ID: http://hdl.handle.net/10400.17/4725
• Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
• Subject(s): HCC CIR; Adult; Aged; Breast Neoplasms / metabolism; Aged, 80 and over; Breast Neoplasms / pathology*; Humans; Female; Breast Neoplasms / surgery; Middle Aged; Carcinoma, Ductal, Breast / metabolism; Carcinoma, Ductal, Breast / secondary*; Carcinoma, Ductal, Breast / surgery; Carcinoma, Lobular / metabolism; Carcinoma, Lobular / secondary*; Carcinoma, Lobular / surgery; Follow-Up Studies; Lymph Nodes / metabolism; Lymph Nodes / pathology*; Lymph Nodes / surgery; Lymphatic Metastasis; Prognosis; Receptor, ErbB-2 / metabolism; Receptors, Estrogen / metabolism; Receptors, Progesterone / metabolism; Young Adult; Sentinel Lymph Node Biopsy*; Retrospective Studies
• Document Type: Journal article
• Language: English
• Contributor(s): Repositório da Unidade Local de Saúde São José

Description

OSNA is a molecular assay for the detection of sentinel node metastasis. TTL emerged as a concept that seems to accurately predict the status of the NSN. Authors tried to confirm this motion. This is a retrospective and multicentric study that analyzed 2164 patients, 579 of whom had positive SN and completion AD. Logistic regression models were performed in order to identify a suitable cutoff to identify patients who benefit from AD. Univariate and multivariate regression analysis showed a relationship between TTL>30000 and the presence of NSN metastasis (OR 2.84, CI 1.99-4.08, p < 0.001). Logistic regression indicated that the cutoff of 30000 copies/μL better discriminates patients with NSN positivity and allows wide use of these criteria. This cutoff value may safely assist clinicians and patients to decide to proceed or not with an AD.